Macro Finance
Novo CEO Doustdar 'Very Optimistic' About CagriSema
Bloomberg Markets·November 4, 2026·1 min read
Novo Nordisk CEO Mike Doustdar says he is 'very optimistic' about the possible launch of the obesity drug CagriSema, hoping for FDA approval at the end of this year and launch early next year. The company boosted its forecast again, as Wegovy and Ozempic buoyed earnings.
Read at Bloomberg MarketsDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.